Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome

Figure 1 The concentrations (mean ± SE) of selected lysophospholipids in mucosal biopsies from irritable bowel syndrome (IBS) patients (n = 15) and healthy controls (n = 9) as measured by UPLC/MS. (A) Patients and controls differ significantly from each other for all presented lysophospholipids, as well as for (B) diacylglycerol and ceramides. LysoPE: Lysophosphatidylethanolamine; LysoPC: Lysophosphatidylcholine. P values are based on Wilcoxon rank sum test with ^bP < 0.01 and ^dP < 0.001.

Figure 2 Partial least squares discriminant analysis (PLS/DA) of GC × GC-Tof-based metabolic profiles for IBS patients (n = 15) and healthy controls (n = 9). Two latent variables (LVs) were used (Q² = 61%).